



1 FW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q93208

Hidenori URATA, et al.

Appln. No.: 10/568,711

Group Art Unit: Unknown

Confirmation No.: Unknown

Examiner: Kimberly White

Filed: February 17, 2006

For: DRUGS CONTAINING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/568,711

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

All documents except the last 4 listed non-patent literature documents, are mentioned in the specification. For the foreign language documents for which English translations are not provided, this constitutes a concise explanation for such documents.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: June 23, 2006

JUN 28 2006



Substitute for Form 1449 A & B/PED

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

Application Number	10/568,711
Confirmation Number	Unknown
Filing Date	February 17, 2006
First Named Inventor	Hidenori URATA
Art Unit	Unknown
Examiner Name	Kimberly White

Attorney Docket Number Q93208

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	US				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
	WO	01/053291	A1	07/26/2001	Teijin Limited	Abstract	
	WO	01/053272	A1	07/26/2001	Teijin Limited	Abstract	
	WO	00/003997	A1	01/27/2000	Teijin Limited	Abstract	
	WO	00/005204	A1	02/03/2000	Shionogi & Co., Ltd.	Abstract	
	WO	98/009949	A1	03/12/1998	Nippon Kayaku Kabushiki Kaisha	Abstract	
	WO	98/018794	A1	05/07/1998	The Green Cross Corporation	Abstract	
	WO	00/051640	A1	09/08/2000	Yoshitomi Pharmaceutical Industries, Ltd.	Abstract	
	WO	02/022595	A1	03/21/2002	Toa Eiyo Ltd.	Abstract	
	WO	01/032214	A1	05/10/2001	Suntory Limited	Abstract	
	WO	02/018378	A1	03/07/2002	Dainippon Pharmaceutical Co., Ltd.	N/A	
	WO	01/012226	A1	02/22/2001	Santen Pharmaceutical Co., Ltd.	Abstract	
	WO	01/032621	A1	05/10/2001	Wakunaga Pharmaceutical Co., Ltd.	Abstract	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		NORMAN M. KAPLAN, MD, "The Deadly Quartet, Upper-Body Obesity, Glucose Intolerance, Hypertriglyceridemia, and Hypertension," Original Investigations, Arch Intern Med, July 1989, Vol. 149, pp. 1514-1520	
		S. K. MAJEED, "Mast Cell Distribution in Rats," Drug Res. 1994, vol. 44 (I), Nr. 3, pp. 370-374	
		RALPH A. DEFRONZO, MD et al., "Insulin Resistance, A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease," Diabetes Care, March 1991, Vol. 14, pp. 173-194	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/568,711
				Confirmation Number	Unknown
				Filing Date	February 17, 2006
				First Named Inventor	Hidenori URATA
				Art Unit	Unknown
				Examiner Name	Kimberly White
Sheet		2	of	4	Attorney Docket Number
		Q93208			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	US				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)		
	JP	10-087493	A	04/07/1998		Abstract
	JP	11-001479	A	01/06/1999		Abstract
	JP	10-251239	A	09/22/1998		Abstract
	JP	8-208654	A	08/13/1996		Abstract
	JP	2001-97957	A	04/10/2001		Abstract
	JP	2000-95770	A	04/04/2000		Abstract

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			Translation ⁶
		DENAN JIN et al., "Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction," Life Sciences, 2002, vol. 71, pp. 437-446			
		YOSHIKAZU SUKENAGA et al., "Development and Application of Chymase Inhibitors, Development of the Chymase Inhibitor as an Anti-Tissue-Remodeling Drug: Myocardial Infarction and Some Other Possibilities," Jpn. J. Pharmacol., 2002, vol. 90, pp. 218-222			
		FUMIHIKO AKAHOSHI et al., "Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiles of Nonpeptidic α -Keto Heterocycles as Novel Inhibitors of Human Chymase," J. Med. Chem., March 2001, vol. 44, pp. 1286-1296			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO		<i>Complete if Known</i>	
<u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u>		Application Number	10/568,711
		Confirmation Number	Unknown
		Filing Date	February 17, 2006
		First Named Inventor	Hidenori URATA
		Art Unit	Unknown
		Examiner Name	Kimberly White
Sheet	3	of	4
		Attorney Docket Number	Q93208

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		OSAMU IIMURA et al., "Effects of Angiotensin Receptor Antagonist and Angiotensin Converting Enzyme Inhibitor on Insulin Sensitivity in Fructose-Fed Hypertensive Rats and Essential Hypertensives," The American Journal of Hypertension, Ltd., April 1995, vol. 8, Part 4, No. 1, pp. 353-357	
		BJORN DAHLOF et al., "Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol," The Lancet, March 2002, vol. 359, No. 9311, pp. 995-1003	
		MIZUO MIYAZAKI, "Development and Application of Chymase Inhibitors," Preface, Jpn. J. Pharmacol., 2002, vol. 90, pp. 205	

Examiner Signature _____ **Date Considered** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO				<i>Complete if Known</i>	
<u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u>				Application Number	10/568,711
				Confirmation Number	Unknown
				Filing Date	February 17, 2006
				First Named Inventor	Hidenori URATA
				Art Unit	Unknown
				Examiner Name	Kimberly White
Sheet	4	of	4	Attorney Docket Number	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		TERUAKI IMADA et al., "Development and Application of Chymase Inhibitors, Therapeutic Potential of a Specific Chymase Inhibitor in Atopic Dermatitis," Jpn. J. Pharmacol., 2002, vol. 90, pp. 214-217	
		MASATOSHI NAKAJIMA et al., "Development and Application of Chymase Inhibitors, Development of a Chymase Inhibitor: Pharmacological Characterization of a Chymase Inhibitor in Inflamed Tissue Remodeling and Fibrosis" Jpn. J. Pharmacol., 2002, vol. 90, pp. 206-209	
		SHINJI TAKAI et al., "Development and Application of Chymase Inhibitors, Effect of Chymase Inhibitor on Vascular Proliferation," Jpn. J. Pharmacol., 2002, vol. 90, pp. 223-227	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.